INTRODUCTION: Despite its proven benefit, studies have reported poor use of perioperative chemotherapy (POC) in bladder cancer patients undergoing radical cystectomy (RC). We evaluated POC use in Quebec between January 2000 and September 2016. METHODS: Using provincial health administrative databases, data were retrospectively collected from patients from two years before RC until December 2016 or death. Logistic regression was used to identify variables predicting POC use. Survival analyses were conducted using Cox regression. Analyzed covariates were age, sex, comorbidities, year of RC, residence and hospital region, distance to hospital, hospital type and size, and hospital's and surgeon's RC volume. RESULTS: A total of 790/4656 patients (17.0%) received POC. Neoadjuvant chemotherapy (NAC) use increased in recent years: 3.5% (2009), 11.2% (2012), and 20.7% (2015). POC use was increased in patients with recent surgery, a younger age, less comorbidities, residing closer to the hospital of surgery, and a high surgeon's RC volume (p<0.05). For patients treated between 2013 and 2016, a younger age (odds ratio [OR] 0.71; 95% confidence interval [CI] 0.64-0.80 per five years), shorter distance to the hospital (OR 0.88; 95% CI 0.77-0.99 per 50 km), surgery in an academic hospital (OR 1.86; 95% CI 1.06-3.29), and recent surgery (OR 1.34; 95% CI 1.14-1.58 per year) independently predicted NAC use. These NAC users had a significantly higher overall survival rate than patients without POC (hazard ratio 0.73; 95% CI 0.55-0.97). Limitations include missing data on pathological staging. CONCLUSIONS: NAC/POC use increased in Quebec but was lower compared to most developed countries. Its use was lower in patients residing further from the hospital and in those treated in non-academic hospitals.
INTRODUCTION: Despite its proven benefit, studies have reported poor use of perioperative chemotherapy (POC) in bladder cancerpatients undergoing radical cystectomy (RC). We evaluated POC use in Quebec between January 2000 and September 2016. METHODS: Using provincial health administrative databases, data were retrospectively collected from patients from two years before RC until December 2016 or death. Logistic regression was used to identify variables predicting POC use. Survival analyses were conducted using Cox regression. Analyzed covariates were age, sex, comorbidities, year of RC, residence and hospital region, distance to hospital, hospital type and size, and hospital's and surgeon's RC volume. RESULTS: A total of 790/4656 patients (17.0%) received POC. Neoadjuvant chemotherapy (NAC) use increased in recent years: 3.5% (2009), 11.2% (2012), and 20.7% (2015). POC use was increased in patients with recent surgery, a younger age, less comorbidities, residing closer to the hospital of surgery, and a high surgeon's RC volume (p<0.05). For patients treated between 2013 and 2016, a younger age (odds ratio [OR] 0.71; 95% confidence interval [CI] 0.64-0.80 per five years), shorter distance to the hospital (OR 0.88; 95% CI 0.77-0.99 per 50 km), surgery in an academic hospital (OR 1.86; 95% CI 1.06-3.29), and recent surgery (OR 1.34; 95% CI 1.14-1.58 per year) independently predicted NAC use. These NAC users had a significantly higher overall survival rate than patients without POC (hazard ratio 0.73; 95% CI 0.55-0.97). Limitations include missing data on pathological staging. CONCLUSIONS: NAC/POC use increased in Quebec but was lower compared to most developed countries. Its use was lower in patients residing further from the hospital and in those treated in non-academic hospitals.
Authors: Girish S Kulkarni; Peter C Black; Srikala S Sridhar; Anil Kapoor; Alexandre R Zlotta; Bobby Shayegan; Ricardo A Rendon; Peter Chung; Theodorus van der Kwast; Nimira Alimohamed; Yves Fradet; Wassim Kassouf Journal: Can Urol Assoc J Date: 2019-01-31 Impact factor: 1.862
Authors: Michel D Wissing; Fabiano Santos; Ahmed S Zakaria; Ana O'Flaherty; Simon Tanguay; Wassim Kassouf; Armen G Aprikian Journal: J Surg Oncol Date: 2019-03-28 Impact factor: 3.454
Authors: Christopher M Booth; Safiya Karim; Kelly Brennan; David Robert Siemens; Yingwei Peng; William J Mackillop Journal: Urol Oncol Date: 2017-12-15 Impact factor: 3.498
Authors: Cora N Sternberg; S Machele Donat; Joaquim Bellmunt; Randall E Millikan; Walter Stadler; Pieter De Mulder; Amir Sherif; Hans von der Maase; Taiji Tsukamoto; Mark S Soloway Journal: Urology Date: 2007-01 Impact factor: 2.649
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Zachary D Reardon; Sanjay G Patel; Harras B Zaid; C J Stimson; Matthew J Resnick; Kirk A Keegan; Daniel A Barocas; Sam S Chang; Michael S Cookson Journal: Eur Urol Date: 2014-01-23 Impact factor: 20.096
Authors: Amandeep Arora; Ahmed S Zugail; Felipe Pugliesi; Xavier Cathelineau; Petr Macek; Yann Barbé; R Jeffrey Karnes; Mohamed Ahmed; Ettore Di Trapani; Francesco Soria; Mario Alvarez-Maestro; Francesco Montorsi; Alberto Briganti; Andrea Necchi; Benjamin Pradere; David D'Andrea; Wojciech Krajewski; Mathieu Roumiguié; Anne Sophie Bajeot; Rodolfo Hurle; Roberto Contieri; Roberto Carando; Jeremy Yuen-Chun Teoh; Morgan Roupret; Daniel Benamran; Guillaume Ploussard; M Carmen Mir; Rafael Sanchez-Salas; Marco Moschini Journal: World J Urol Date: 2022-04-30 Impact factor: 4.226